Explaining Pharmaceutical R&D Growth Rates at the Industry Level: New Perspectives and Insights

Abstract

This paper uses aggregate data for the major pharmaceutical companies in the U.S. to study the rate of growth in pharmaceutical R&D intensity over the period from 1952 to 2001. The theoretical model argues and the empirical findings suggest that pharmaceutical R&D spending increases with real drug prices, after holding constant other determinants of R&D. Simulations based on our multiple regression model indicate that the capitalized value of pharmaceutical R&D spending would have been about 30 percent lower if the federal government had limited the rate of growth in drug price increases to the rate of growth in the general consumer price index during the period 1980 to 2001. Moreover, a drug price control regime would have resulted in 330 to 365 fewer new drugs brought to the global market during that same time period.Health and Safety